Kurma Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Avidicure is a cancer care company focused on enhancing immune system performance through innovative therapeutic approaches. The company is developing a novel class of antibodies known as AVC-Boosters, which are engineered to act as dual agonists. This multifunctional modality aims to deliver targeted and effective monotherapy, offering broad applicability in oncology. Currently operating in stealth mode, Avidicure is dedicated to pioneering advancements in cancer treatment that prioritize safety and efficacy.

Brink Therapeutics is a biotechnology research firm specializing in cell therapy development. It focuses on using reprogrammed recombinases, a type of enzyme that can alter DNA, to create innovative therapies. The company's proprietary technology, designed for in-vivo cell and gene therapy, mimics natural selection to enhance proteins and accelerate testing of recombinases. This enables researchers to develop more efficient and controlled therapies for complex diseases, including cancer and inherited conditions.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Omnidoc is a tele-expertise platform that enables healthcare professionals to exchange medical opinions efficiently. It is designed to facilitate phone-based medical verification for patients eligible for health insurance, allowing medical institutions and private physicians to obtain informal opinions. The platform strengthens the connections between primary care providers and specialized physicians while centralizing requests from correspondents. Omnidoc also assists clients in discovering and contacting relevant doctors and organizations, aimed at improving the quality and security of exchanged opinions. Additionally, it automates various administrative tasks, streamlining processes within healthcare communication.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a significant discovery that identifies CXCR4 as a master regulator of inflammation. This breakthrough positions Ermium Therapeutics to create therapies that control interferons through plasmacytoid dendritic cells, offering potential new treatment options for patients suffering from these conditions. The company has secured a worldwide exclusive license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which supported the project's academic maturation. Ermium Therapeutics has also been recognized for its innovative approach, winning the i-Lab 2019 award from the French Ministry of Research and Higher Education.

DAMAE Medical, established in 2014 and headquartered in Paris, France, specializes in developing innovative medical devices for dermatological applications. The company's flagship product, OCTAV, employs advanced optical imaging technology to provide dermatologists with high-resolution, in-depth images of skin tissue, similar to traditional histology, but without the need for tissue excision or processing. This non-invasive, in-vivo imaging modality enables precise, efficient, and rapid evaluation of skin tumors, aiding in the diagnosis of skin cancers. DAMAE Medical's mission is to harness the power of bio-photonics to revolutionize medical imaging and diagnosis in dermatology.

NaoX Technologies is a company focused on the prevention of neurological disorders through innovative technology. It develops wireless headphones equipped with integrated sensors that passively monitor brain vibrations to record electroencephalogram data in real time. This data is then aggregated and presented on a software dashboard for healthcare providers, facilitating better diagnosis and treatment for patients. The company's mission is to democratize access to neurological disorder prevention, aiming to enhance patient outcomes and support recovery from mental illness.

Armgo Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics aimed at treating debilitating cardiac, skeletal muscular, and neurological disorders. The company specializes in Rycals, which are innovative calcium release channel stabilizers that target the ryanodine receptor/calcium release channel located on the sarcoplasmic/endoplasmic reticulum of cells. These therapeutics are designed to address various conditions, including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Incorporated in 2004, Armgo Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Omnidoc is a tele-expertise platform that enables healthcare professionals to exchange medical opinions efficiently. It is designed to facilitate phone-based medical verification for patients eligible for health insurance, allowing medical institutions and private physicians to obtain informal opinions. The platform strengthens the connections between primary care providers and specialized physicians while centralizing requests from correspondents. Omnidoc also assists clients in discovering and contacting relevant doctors and organizations, aimed at improving the quality and security of exchanged opinions. Additionally, it automates various administrative tasks, streamlining processes within healthcare communication.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Argobio Studio is a start-up studio dedicated to developing innovative therapeutic solutions and launching biotech firms. The studio sources advanced early-stage projects from top European academic research institutions, focusing on areas such as rare diseases, neurological disorders, oncology, and immunology. Argobio aims to cultivate these projects to create promising platform technologies for therapeutic products. By providing financial support and operational expertise, the studio facilitates the growth of early-stage biotechnology initiatives, enabling startups to enhance their medicinal and drug research processes.

Corlieve Therapeutics SAS is a biotechnology company based in Paris, France, dedicated to developing innovative therapeutic options for patients suffering from severe neurological disorders. Founded in 2019, the company focuses on a lead project that targets aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) through a gene therapy approach. This novel AAV gene therapy program aims to address refractory TLE, leveraging scientific research from notable institutions such as INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. By advancing its therapeutic strategies, Corlieve Therapeutics seeks to enhance the quality of life for individuals impacted by these challenging conditions.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Sensome SAS, established in 2014 and based in Massy, France, specializes in developing and manufacturing medical micro-sensors. The company's core business involves transforming invasive vascular medical devices into connected healthcare devices, utilizing AI-powered micro-sensor technology. This technology enables real-time detection of the composition of blockages, particularly in the brain during stroke treatment. Sensome's innovative approach aims to overcome limitations of traditional vascular imaging techniques, initially focusing on vascular access devices, with future plans to equip implantable devices for neurovascular, peripheral vascular, and cardiovascular indications.

Cardiologs is a medical technology company founded in 2014, focused on transforming cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million cardiac recordings, which is continuously expanding and supported by numerous clinical publications that validate its diagnostic performance. Cardiologs aims to democratize expert cardiac care globally by providing healthcare practitioners and clinicians with advanced tools, including an automatic heart disorder screener and electrocardiogram analysis services powered by machine learning algorithms. This technology enhances physicians' capabilities in interpreting electrocardiograms, making expert cardiac diagnostics more scalable and accessible.

Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a significant discovery that identifies CXCR4 as a master regulator of inflammation. This breakthrough positions Ermium Therapeutics to create therapies that control interferons through plasmacytoid dendritic cells, offering potential new treatment options for patients suffering from these conditions. The company has secured a worldwide exclusive license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which supported the project's academic maturation. Ermium Therapeutics has also been recognized for its innovative approach, winning the i-Lab 2019 award from the French Ministry of Research and Higher Education.

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for rare diseases, specifically targeting hereditary angioedema (HAE) and other conditions mediated by bradykinin B2 receptors. The company aims to provide alternatives to injectable treatments through its novel small molecules. Pharvaris' lead drug candidate, PHA121, is a potent oral bradykinin B2 receptor antagonist currently undergoing Phase 1 clinical trials. The company's expertise stems from its co-founders, who include key figures involved in the development of icatibant, a well-established treatment for HAE. Pharvaris is committed to addressing significant unmet medical needs in the field of bradykinin-mediated diseases.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Sensome SAS, established in 2014 and based in Massy, France, specializes in developing and manufacturing medical micro-sensors. The company's core business involves transforming invasive vascular medical devices into connected healthcare devices, utilizing AI-powered micro-sensor technology. This technology enables real-time detection of the composition of blockages, particularly in the brain during stroke treatment. Sensome's innovative approach aims to overcome limitations of traditional vascular imaging techniques, initially focusing on vascular access devices, with future plans to equip implantable devices for neurovascular, peripheral vascular, and cardiovascular indications.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Cardiologs is a medical technology company founded in 2014, focused on transforming cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million cardiac recordings, which is continuously expanding and supported by numerous clinical publications that validate its diagnostic performance. Cardiologs aims to democratize expert cardiac care globally by providing healthcare practitioners and clinicians with advanced tools, including an automatic heart disorder screener and electrocardiogram analysis services powered by machine learning algorithms. This technology enhances physicians' capabilities in interpreting electrocardiograms, making expert cardiac diagnostics more scalable and accessible.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Sensome SAS, established in 2014 and based in Massy, France, specializes in developing and manufacturing medical micro-sensors. The company's core business involves transforming invasive vascular medical devices into connected healthcare devices, utilizing AI-powered micro-sensor technology. This technology enables real-time detection of the composition of blockages, particularly in the brain during stroke treatment. Sensome's innovative approach aims to overcome limitations of traditional vascular imaging techniques, initially focusing on vascular access devices, with future plans to equip implantable devices for neurovascular, peripheral vascular, and cardiovascular indications.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

DAMAE Medical, established in 2014 and headquartered in Paris, France, specializes in developing innovative medical devices for dermatological applications. The company's flagship product, OCTAV, employs advanced optical imaging technology to provide dermatologists with high-resolution, in-depth images of skin tissue, similar to traditional histology, but without the need for tissue excision or processing. This non-invasive, in-vivo imaging modality enables precise, efficient, and rapid evaluation of skin tumors, aiding in the diagnosis of skin cancers. DAMAE Medical's mission is to harness the power of bio-photonics to revolutionize medical imaging and diagnosis in dermatology.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development, manufacture, and marketing of innovative patient monitoring systems. The company's primary focus is on delivering critical indicators related to tissue perfusion, which are essential for clinicians in assessing patient health. The recent launch of the IKORUS® monitoring system addresses a significant gap in patient monitoring by facilitating the early detection of microcirculatory alterations. This system not only enhances clinical assessment of intestinal tissue perfusion but also guides novel circulatory therapies and informs new approaches to resuscitation. By providing these tools, Advanced Perfusion Diagnostics aims to reduce patient complications and overall treatment costs, ultimately improving therapeutic practices and patient outcomes.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for rare diseases, specifically targeting hereditary angioedema (HAE) and other conditions mediated by bradykinin B2 receptors. The company aims to provide alternatives to injectable treatments through its novel small molecules. Pharvaris' lead drug candidate, PHA121, is a potent oral bradykinin B2 receptor antagonist currently undergoing Phase 1 clinical trials. The company's expertise stems from its co-founders, who include key figures involved in the development of icatibant, a well-established treatment for HAE. Pharvaris is committed to addressing significant unmet medical needs in the field of bradykinin-mediated diseases.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development, manufacture, and marketing of innovative patient monitoring systems. The company's primary focus is on delivering critical indicators related to tissue perfusion, which are essential for clinicians in assessing patient health. The recent launch of the IKORUS® monitoring system addresses a significant gap in patient monitoring by facilitating the early detection of microcirculatory alterations. This system not only enhances clinical assessment of intestinal tissue perfusion but also guides novel circulatory therapies and informs new approaches to resuscitation. By providing these tools, Advanced Perfusion Diagnostics aims to reduce patient complications and overall treatment costs, ultimately improving therapeutic practices and patient outcomes.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asceneuron SA, established in 2012 and headquartered in Lausanne, Switzerland, is a biotechnology subsidiary of Merck KGaA dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. The company focuses on progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to provide effective treatments where none currently exist or are limited in their benefits. Asceneuron operates by targeting the underlying causes of these debilitating conditions, such as abnormal tau protein deposits, with the goal of developing orally bioavailable therapeutics that can improve patients' lives and address the growing healthcare burden posed by neurodegenerative diseases.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

BliNK Biomedical SAS, established in 2014 and based in Lyon, France, is a biotechnology company focused on the discovery and development of novel monoclonal antibody therapies for life-threatening diseases like cancer, with an emphasis on immuno-oncology targets. The company's proprietary B cell technology platform facilitates the efficient isolation of antibody-producing cells from various species, enabling the identification of unique therapeutic antibodies even for challenging targets. BliNK's lead program involves a monoclonal antibody targeting an immune checkpoint to stimulate the body's immune response against tumors.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

ABM Pharma is a partner of the entire pharmacy network in the home care of patients, today more than 5000 pharmacies are clients. ABM Pharma technicians work with more than 30,000 patients.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in hearts affected by disease. The company specializes in addressing genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor seeks to provide innovative solutions that enable healthcare professionals to improve cardiac function in patients suffering from these conditions.